AP NEWS

Syros to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

July 31, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 31, 2018--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 7, 2018 to report its second quarter 2018 financial results and provide a corporate update.

To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 8675009. A webcast of the call will also be available on the Investors & Media section of the Syros website at  www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005005/en/

CONTACT: Media Contact:

Syros Pharmaceuticals

Naomi Aoki, 617-283-4298

naoki@syros.com

or

Investor Contact:

Stern Investor Relations, Inc.

Hannah Deresiewicz, 212-362-1200

hannahd@sternir.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL

SOURCE: Syros Pharmaceuticals

Copyright Business Wire 2018.

PUB: 07/31/2018 08:01 AM/DISC: 07/31/2018 08:01 AM

http://www.businesswire.com/news/home/20180731005005/en

AP RADIO
Update hourly